INDSWFTLTD Stock Overview
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ind-Swift Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹22.10 |
| 52 Week High | ₹31.20 |
| 52 Week Low | ₹7.65 |
| Beta | -0.25 |
| 1 Month Change | -17.69% |
| 3 Month Change | 13.92% |
| 1 Year Change | 154.02% |
| 3 Year Change | 342.00% |
| 5 Year Change | 346.46% |
| Change since IPO | -89.40% |
Recent News & Updates
Shareholder Returns
| INDSWFTLTD | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -9.2% | -3.4% | -3.7% |
| 1Y | 154.0% | 53.6% | 38.4% |
Return vs Industry: INDSWFTLTD exceeded the Indian Pharmaceuticals industry which returned 53.6% over the past year.
Return vs Market: INDSWFTLTD exceeded the Indian Market which returned 38.4% over the past year.
Price Volatility
| INDSWFTLTD volatility | |
|---|---|
| INDSWFTLTD Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: INDSWFTLTD's share price has been volatile over the past 3 months.
Volatility Over Time: INDSWFTLTD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 1,200 | Gopal Munjal | www.indswiftltd.com |
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynaecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-allergic, neurology, and oncology. The company also provides Ayurvedic products, as well as contract research and manufacturing services.
Ind-Swift Limited Fundamentals Summary
| INDSWFTLTD fundamental statistics | |
|---|---|
| Market cap | ₹1.20b |
| Earnings (TTM) | ₹297.88m |
| Revenue (TTM) | ₹4.73b |
4.0x
P/E Ratio0.3x
P/S RatioIs INDSWFTLTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDSWFTLTD income statement (TTM) | |
|---|---|
| Revenue | ₹4.73b |
| Cost of Revenue | ₹2.71b |
| Gross Profit | ₹2.02b |
| Other Expenses | ₹1.72b |
| Earnings | ₹297.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 5.50 |
| Gross Margin | 42.73% |
| Net Profit Margin | 6.30% |
| Debt/Equity Ratio | -136.8% |
How did INDSWFTLTD perform over the long term?
See historical performance and comparison